Henrik Hjorth-Hansen

St. Olavs Hospital · Norwegian University of Science and Technology

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

NIH RePORTER

Trial papers

PubMed author-name match

Trials

Studies that name Henrik Hjorth-Hansen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:23 UTC. Open this list on ClinicalTrials.gov

Ph2
NCT03831776 · Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis
St. Olavs Hospital · completed · Chronic Myeloid Leukemia · principal investigator
Ph2
NCT01725204 · Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia
Norwegian University of Science and Technology · completed · Leukemia, Myeloid, Chronic-Phase · study chair
Ph2
NCT00852566 · Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia
Norwegian University of Science and Technology · completed · Chronic Myeloid Leukemia · study chair

Grants

NIH projects from RePORTER, fetched 2026-11-12 09:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:23 UTC. The ranking covers the 200 most relevant of 18 PubMed records, and a shared surname and initials can bring in a namesake. All 18 on PubMed